Drug name - Invokana
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7943788 | JANSSEN PHARMS | Glucopyranoside compound |
Jul, 2027
(4 years from now) | |
| US8513202 | JANSSEN PHARMS | Crystalline form of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate |
Dec, 2027
(5 years from now) | |
| US7943582 | JANSSEN PHARMS | Crystalline form of 1-(β-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate |
Feb, 2029
(6 years from now) | |
| CN1829728A | JANSSEN PHARMS | Novel Compounds |
Oct, 2011
(10 years ago) | |
| CN101111492B | JANSSEN PHARMS | Indole Derivatives |
Mar, 2017
(5 years ago) | |
| CN101111492A | JANSSEN PHARMS | Indol Derivative |
Mar, 2017
(5 years ago) | |
| CN103214471B | JANSSEN PHARMS | Preparation Method Of Compound With Sodium-Dependent Glucose Transporter Inhibitory Activity |
Jul, 2024
(1 year, 9 months from now) | |
| CN103214471A | JANSSEN PHARMS | Novel Compounds |
Jul, 2024
(1 year, 9 months from now) | |
| CN101573368B | JANSSEN PHARMS | Crystalline 1 - ([Beta] - D-Glucopyranosyl) - 4-Methyl-3 - [5 - (4-Fluorophenyl) - 2-Thienyl] Benzene Hemihydrate |
Dec, 2027
(5 years from now) | |
| CN101573368A | JANSSEN PHARMS | A Novel Crystalline Form Of 1-(Beta-D-Glucopyranosyl)-4-Methyl-3-[5-(4-Fluorophenyl)-2-Thienylmethyl]Benzene Hemihydrate With Favourable Characteristics Has Its X-Ray Powder Diffraction Pattern And/Or By Its Infrared Spectrum. |
Dec, 2027
(5 years from now) | |
| IN200600734P4 | JANSSEN PHARMS | Glucopyranoside Compound |
Jul, 2024
(1 year, 9 months from now) | |
| IN232231B | JANSSEN PHARMS | 1-(-D-Glucopyranosyl)-3-(2-Thienylmethyl)Benzene Derivatives |
Jul, 2024
(1 year, 9 months from now) | |
| IN200903871P4 | JANSSEN PHARMS | Crystalline Form Of 1-(B-D-Glucopyranosyl)-4-Methyl-3-[5-(4-Fluorophenyl)-2-Thienylmethyl] Benzene Hemihydrate |
Dec, 2027
(5 years from now) | |
| IN286412B | JANSSEN PHARMS | Crystalline Form Of 1-(B-Dglucopyranosyl)- 4-Methyl-3-[5-(4- Fluorophenyl)-2- Thienylmethyl] Benzene Hemihydrate |
Dec, 2027
(5 years from now) | |
| EP2896397B2 | JANSSEN PHARMS | Novel Compounds Having Inhibitory Activity Against Sodium-Dependant Glucose Transporter |
Jul, 2024
(1 year, 9 months from now) | |
| EP1654269A1 | JANSSEN PHARMS | Novel Compounds |
Jul, 2024
(1 year, 9 months from now) | |
| EP3251679A1 | JANSSEN PHARMS | Novel Compounds Having Inhibitory Activity Against Sodium-Dependant Glucose Transporter |
Jul, 2024
(1 year, 9 months from now) | |
| EP2514756B1 | JANSSEN PHARMS | Novel Compounds Having Inhibitory Activity Against Sodium-Dependant Glucose Transporter |
Jul, 2024
(1 year, 9 months from now) | |
| EP3251679B1 | JANSSEN PHARMS | Novel Compounds Having Inhibitory Activity Against Sodium-Dependant Glucose Transporter |
Jul, 2024
(1 year, 9 months from now) | |
| EP1654269B1 | JANSSEN PHARMS | Novel Compounds |
Jul, 2024
(1 year, 9 months from now) | |
| EP2896397B1 | JANSSEN PHARMS | Novel Compounds Having Inhibitory Activity Against Sodium-Dependant Glucose Transporter |
Jul, 2024
(1 year, 9 months from now) | |
| EP2514756A1 | JANSSEN PHARMS | Novel Compounds Having Inhibitory Activity Against Sodium-Dependant Glucose Transporter |
Jul, 2024
(1 year, 9 months from now) | |
| EP2896397A1 | JANSSEN PHARMS | Novel Compounds Having Inhibitory Activity Against Sodium-Dependant Glucose Transporter |
Jul, 2024
(1 year, 9 months from now) | |
| EP2102224B1 | JANSSEN PHARMS | Crystalline Form Of 1- (ß-D-Glucopyranosyl) -4 -Methyl- 3- [5- (4 -Fluorophenyl) -2-Thienylmethyl]Benzene Hemihydrate |
Dec, 2027
(5 years from now) | |
| EP2102224A1 | JANSSEN PHARMS | Crystalline Form Of 1- (ß-D-Glucopyranosyl) -4 -Methyl- 3- [5- (4 -Fluorophenyl) -2-Thienylmethyl]Benzene Hemihydrate |
Dec, 2027
(5 years from now) | |
| EP2102224B2 | JANSSEN PHARMS | Crystalline Form Of 1- (ß-D-Glucopyranosyl) -4 -Methyl- 3- [5- (4 -Fluorophenyl) -2-Thienylmethyl]Benzene Hemihydrate |
Dec, 2027
(5 years from now) | |
| EP1651658B2 | JANSSEN PHARMS | Novel Compounds Having Inhibitory Activity Against Sodium-Dependant Transporter |
Nov, 2028
(6 years from now) | |
| EP1651658A1 | JANSSEN PHARMS | Novel Compounds Having Inhibitory Activity Against Sodium-Dependant Transporter |
Nov, 2028
(6 years from now) | |
| EP1651658B1 | JANSSEN PHARMS | Novel Compounds Having Inhibitory Activity Against Sodium-Dependant Transporter |
Nov, 2028
(6 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8222219 | JANSSEN PHARMS | Glucopyranoside compound |
Apr, 2025
(2 years from now) | |
| US10617668 | JANSSEN PHARMS | Pharmaceutical formulations |
May, 2031
(8 years from now) | |
Drugs and Companies using CANAGLIFLOZIN ingredient
Treatment: Treatment of type 2 diabetes mellitus; reduction of risk of major adverse cardiovascular events in the treatment of type 2 diabetes mellitus patients; reduction of risk of end stage kidney disease, doubling of serum creatinine, cardiovascular death, and hospitalization for heart failure in the treatment of type 2 diabetes mellitus patients; Reduction of risk of end stage kidney disease, doubling of serum creatinine, cardiovascular death, and hospitalization for heart failure in the treatment of type 2 diabetes mellitus patients with 100 mg canagliflozin per day; reduction of risk of end stage kidney disease, doubling of serum creatinine, cardiovascular death, and hospitalization for heart failure in the treatment of type 2 diabetes mellitus patients with 300 mg canagliflozin per day; treatment of type 2 diabetes mellitus with 300 mg canagliflozin per day; reduction of risk of end stage kidney disease, doubling of serum creatinine, cardiovascular death, and hospitalization for heart failure in the treatment of type 2 diabetes mellitus patients; reduction of risk of major adverse cardiovascular events in the treatment of type 2 diabetes mellitus patients with 300 mg canagliflozin per day; reduction of risk of major adverse cardiovascular events in the treatment of type 2 diabetes mellitus patients with 100 mg canagliflozin per day; reduction of risk of major adverse cardiovascular events in the treatment of type 2 diabetes mellitus patients; treatment of type 2 diabetes mellitus with 100 mg canagliflozin per day; treatment of type 2 diabetes mellitus
Dosage: TABLET;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 100MG | TABLET;ORAL | Prescription |
| 300MG | TABLET;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.